Re: Yet another article on the buyout..
Gary I agree, the stock was over 40 when they had nothing and now with the ovarian drug plus all the other drugs in partnership and the in house trials they stole the company. If they would have done nothing until they received final approval and the other trials moved forward the stock price would have been at least 25. At that point a buyout at 50 would have been attainable. I hope they vote it down and competitive bids come in much higher. The question is why did Mark and the BOD sell us out so soon and before final approval????